HLA-G and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), HLA-G and PD-L1 expression were boosted in a dose-dependent manner by several chemotherapeutic agents, among which pemetrexed promoted the glycosylation of HLA-G and PD-L1 consistently as a belt-and-braces approach to the tumor cell immune escape [201].